These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37251947)

  • 41. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
    Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
    Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.
    Kobayashi K; Suzuki K; Hiraide M; Aoyama T; Yokokawa T; Shikibu S; Hashimoto K; Iikura Y; Sato H; Sugiyama E; Tajima M; Hama T
    Oncology; 2020; 98(4):237-242. PubMed ID: 31935736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pembrolizumab Induced Acute Kidney Injury and Liver Injury in a Patient with Malignant Melanoma.
    DeVries JD; Huber M; Sulaiman R; Singal AK
    S D Med; 2022 Apr; 75(4):162-165. PubMed ID: 35709347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil.
    Ding M; Deng C; Liu X; Jiang S; Gao Y; Fan D; Zhou Y; He J; Liu C
    Front Immunol; 2023; 14():1132692. PubMed ID: 37223099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.
    Tanaka R; Fujisawa Y; Sae I; Maruyama H; Ito S; Hasegawa N; Sekine I; Fujimoto M
    Jpn J Clin Oncol; 2017 Feb; 47(2):175-178. PubMed ID: 28173241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient.
    Kondo T; Kawachi S; Nakatsugawa M; Takeda A; Kikawada N; Aihara Y; Okimura A; Hirano H; Ogawa Y; Tsukahara K
    Auris Nasus Larynx; 2022 Aug; 49(4):721-726. PubMed ID: 33612350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
    Owen CN; Bai X; Quah T; Lo SN; Allayous C; Callaghan S; Martínez-Vila C; Wallace R; Bhave P; Reijers ILM; Thompson N; Vanella V; Gerard CL; Aspeslagh S; Labianca A; Khattak A; Mandala M; Xu W; Neyns B; Michielin O; Blank CU; Welsh SJ; Haydon A; Sandhu S; Mangana J; McQuade JL; Ascierto PA; Zimmer L; Johnson DB; Arance A; Lorigan P; Lebbé C; Carlino MS; Sullivan RJ; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):917-925. PubMed ID: 33798657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
    Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
    In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pembrolizumab-Induced Delayed-Onset Hepatitis.
    Kanaoka K; Moriizumi K; Okada H; Iwahashi K; Tsuji H; Yasuoka H; Minami S
    Case Rep Gastroenterol; 2020; 14(3):586-592. PubMed ID: 33250701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma.
    Wang Q; Hu B
    Ann Transl Med; 2019 Jun; 7(11):247. PubMed ID: 31317017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
    Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report.
    Sasaki K; Kobayashi S; Kudo M; Sugimoto M; Takahashi S; Nakamura Y; Kawazoe A; Shitara K; Kinoshita T; Gotohda N
    Surg Case Rep; 2021 Dec; 7(1):267. PubMed ID: 34928436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.
    Wu JY; Kang K; Yi J; Yang B
    World J Clin Cases; 2022 Jun; 10(18):6110-6118. PubMed ID: 35949835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.